Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASolute 305
2025-524928-21-00Phase 3Authorised
- Sponsor
- Revolution Medicines
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of zoldonrasib in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Revolution Medicines. Primary endpoints: Progression-free survival by investigator and Overall survival. Planned start Oct 2026; status: authorised.
02
Drugs
zoldonrasib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2025-524928-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524928-21-00.